Susanna Swoboda

Susanna Swoboda

Auto-generated profile, based on publicly available information

Susanna Swoboda

Department of Hematology, Oncology, and Cancer Immunology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 July 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
ABAlexej Ballhausen
Alexej Ballhausen
SSSusanna Swoboda
Susanna Swoboda
DHDavid Horst
David Horst
SFStefan Fruehauf
Stefan Fruehauf
UGUllrich Graeven
Ullrich Graeven
DMDominik Paul Modest
Dominik Paul Modest
Purpose: Tumor immune cell infiltration patterns in the tumor microenvironment serve as prognostic biomarkers in metastatic colorectal cancer. This study analyzed the spatially resolved tumor immune microenvironment for prognostic and predictive impact in patients with RAS wild-type metastatic colorectal cancer receiving 5-fluoruracil/folinic acid ± panitumumab (Pmab) maintenance after Pmab + fluorouracil, folinic acid, and oxaliplatin induction (PanaMa AIO KRK0212; NCT01991873). Patients and Methods: Twelve immune parameters (lymphocyte markers: CD3, CD8, CD45RO, FOXP3, CD20, granzyme B, and perforin; immune checkpoints: PD-1, PD-L1, IDO1, and LAG3; and monocyte marker CD163) were quantified in spatially resolved tumor and stroma regions [invasive-margin (Inv) and center (Cen)] on tissue microarrays from available surgical resections using digital pathology. Prognostic and predictive associations were assessed using percentile cutoffs, immunoscore (IS), PD-L1 combined positive score, and an immunoactivation score (IAS). The median progression-free (PFS) and overall survival (OS) were estimated by the Kaplan–Meier method, log rank test, and Cox regression. Results: In 194 patients, low CD163 and high PD-1 in the tumor center were independent prognostic factors for prolonged PFS, whereas high central LAG3 was associated with improved OS. Pmab maintenance conferred PFS benefit in patients with low CD3InvStr, CD8Inv, LAG3CenTum, CD163CenTum, and IS and high CD45ROCen. CD45ROCen high and LAG3Cen low also predicted OS benefit. A positive IAS (≥2 predictive markers) identified patients deriving significant PFS (HR = 0.50; 95% confidence interval, 0.32–0.76; P < 0.001) and OS (HR = 0.54; 95% confidence interval, 0.33–0.86; P = 0.009) benefit from Pmab. Conclusions: Immune microenvironment factors, including CD3, CD8, CD163, LAG3, CD45RO, IS, and IAS, predict benefit from Pmab maintenance, suggesting immune activation as a key component of anti-EGFR efficacy.


1 October 2025
Verified
Other
Open access
ABAlexej Ballhausen
Alexej Ballhausen
SSSusanna Swoboda
Susanna Swoboda
DHDavid Horst
David Horst
SFStefan Fruehauf
Stefan Fruehauf
UGUllrich Graeven
Ullrich Graeven
DMDominik Paul Modest
Dominik Paul Modest
Interaction of positive/negative Immunoscore and Immunoactivation Score with maintenance treatment in terms of PFS and OS in the PanaMa trial.

1 October 2025
Verified
Other
Open access
ABAlexej Ballhausen
Alexej Ballhausen
SSSusanna Swoboda
Susanna Swoboda
DHDavid Horst
David Horst
SFStefan Fruehauf
Stefan Fruehauf
UGUllrich Graeven
Ullrich Graeven
DMDominik Paul Modest
Dominik Paul Modest
P, Hazard Ratios and 95% Confidence Intervals regarding OS of immunoexpression after exclusion of cases with BRAF V600E and MSI – Maintenance Set.

1 October 2025
Verified
Other
Open access
ABAlexej Ballhausen
Alexej Ballhausen
SSSusanna Swoboda
Susanna Swoboda
DHDavid Horst
David Horst
SFStefan Fruehauf
Stefan Fruehauf
UGUllrich Graeven
Ullrich Graeven
DMDominik Paul Modest
Dominik Paul Modest
Analysis of overall survival within the maintenance therapy set by high/low immune expression, tumor region and treatment arm.

1 October 2025
Verified
Other
Open access
ABAlexej Ballhausen
Alexej Ballhausen
SSSusanna Swoboda
Susanna Swoboda
DHDavid Horst
David Horst
SFStefan Fruehauf
Stefan Fruehauf
UGUllrich Graeven
Ullrich Graeven
DMDominik Paul Modest
Dominik Paul Modest
Overview of antibodies used for staining and cutoffs in TMA analysis.